Scarica l'app Stockscreener
0.97
2.02%
-0.02
Precedente Chiudi:
$0.99
Aprire:
$0.9817
Volume 24 ore:
4,202
Relative Volume:
0.00
Capitalizzazione di mercato:
$8.49M
Reddito:
$1.52M
Utile/perdita netta:
$-13.97M
Rapporto P/E:
-0.318
EPS:
-3.05
Flusso di cassa netto:
$-13.29M
1 W Prestazione:
+3.35%
1M Prestazione:
-11.82%
6M Prestazione:
+24.37%
1 anno Prestazione:
-23.02%
Intervallo 1D:
$0.9817
$0.9817
Intervallo di 1 settimana:
$0.90
$1.06
Portata 52W:
$0.55
$3.06
Predictive Oncology Inc Stock (POAI) Company Profile
Nome
Predictive Oncology Inc
Settore
Industria
Telefono
412-432-1500
Indirizzo
91 43RD STREET, PITTSBURGH, MN
Confronta POAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
0.9817 | 8.49M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
509.00 | 200.02B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
176.16 | 49.02B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.49 | 43.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
250.19 | 36.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
225.27 | 15.70B | 2.90B | 467.20M | 306.90M | 6.37 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
Predictive Oncology Inc Borsa (POAI) Ultime notizie
Predictive Oncology develops liver toxicity models for Labcor By Investing.com - Investing.com South Africa
Predictive Oncology Develops 3D Liver Toxicity Models for Labcorp - marketscreener.com
Predictive Oncology Inc. Develops Functional 3D Organoid Models Exclusively for Labcorp - marketscreener.com
Labcorp (LH) Gains Exclusive 3D Liver Models from Predictive Onc - GuruFocus
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - The Manila Times
Revolutionary 3D Organoid Models: How Predictive Oncology's Exclusive Labcorp Deal Transforms Drug Testing - Stock Titan
Predictive Oncology Faces Nasdaq Delisting Notice - TipRanks
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Major AI Breakthrough in Cancer Research: Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan
SEC Form 424B5 filed by Predictive Oncology Inc. - Quantisnow
'It's not something you choose to do, it's something you have to do': CEO & artist shares story - WTAE
Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Predictive Oncology (POAI) Advances AI-Driven Cancer Drug Discov - GuruFocus
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement Dispute | POAI Stock News - GuruFocus
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition | POAI Stock News - GuruFocus
Predictive Oncology harnesses AI for drug discovery - Investing.com
Predictive Oncology moves to leverage biobank using AI - TipRanks
Predictive Oncology harnesses AI for drug discovery By Investing.com - Investing.com Nigeria
Predictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor Samples - Nasdaq
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery - Stock Titan
Predictive Oncology issued shareholder letter - TipRanks
Predictive Oncology (POAI) Showcases Recent Achievements and Future Plans | POAI Stock News - GuruFocus
Predictive Oncology Inc. Issues Shareholder Letter Titled, - GuruFocus
Predictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision Oncology - Nasdaq
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: ... - Bluefield Daily Telegraph
Revolutionary AI Platform Expands into $14.5B Biomarker Market with Game-Changing Cancer Prediction Technology - Stock Titan
Predictive Oncology reports loss, but has "meaningfully expanded the potential" of its AI platform - The Business Journals
Predictive Oncology Inc. Reports Q1 2025 Earnings - TipRanks
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology (POAI) Sees Significant Revenue Growth in Q1 2025 | POAI Stock News - GuruFocus
Predictive Oncology Inc Azioni (POAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):